checkAd

TYME Appoints Frank L. Porfido as Chief Financial Officer

Nachrichtenquelle: Business Wire (engl.)
13.05.2021, 15:05  |  147   |   |   

TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that it has appointed Frank L. Porfido as its Chief Financial Officer, effective shortly after the Company files its annual report on Form 10-K.

Mr. Porfido is a well-established biotech and pharmaceutical industry executive with over 25 years of strategic financial leadership expertise. Throughout his career, Mr. Porfido has demonstrated a track record of building and leading cross-functional teams. Collectively, he spent over 15 years at Novartis in various leadership roles, including serving as the Global Head of Finance for their Oncology Business Unit and Head of Global Finance for their Oncology Translational Medicines (OTM) Unit. He was responsible for developing its global strategic plan for a $15 billion business unit and in his OTM position he was a member of a leadership team that managed the early-stage Oncology pipeline.

“The appointment of our Chief Financial Officer is an important milestone for the Company as we are diligently working to finalize the strategic review of our pipeline development programs. We are pleased to have garnered the attention of such a well-suited candidate and welcome Frank to our executive management team to fill this important role,” commented Richie Cunningham, Chief Executive Officer of TYME. “His appointment comes at a perfect time and we believe his leadership and expertise will be an invaluable component as we position the Company moving forward and execute on the strategies ahead. With the addition of Frank, I believe we now have the right team in place to successfully unlock the full potential and vision of TYME. We look forward to providing more updates as we rollout the results from our strategic review in June.”

Mr. Porfido added, “TYME is poised for a transformational year and I am excited to join the team at such a pivotal time in the Company’s history. I believe there is tremendous potential for the Company ahead and the expertise developing and implementing strategic business plans that I’ve gathered over the course of my career will help to provide the necessary insight as TYME advances its efforts. I look forward to hitting the ground running and helping the team build momentum in the near and long term.”

Seite 1 von 3
Tyme Technologies Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

TYME Appoints Frank L. Porfido as Chief Financial Officer TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced that it has appointed Frank L. Porfido as its Chief Financial Officer, …

Nachrichten des Autors

Titel
Titel
Titel
Titel